• Bausch Health flagged an increase to full-year 2026 adjusted EBITDA excluding acquired IPR&D guidance, based on preliminary third-quarter results.
• The update cited stronger business performance expectations for the rest of 2026, supported by prevailing foreign exchange rates.
• The company reported 13 consecutive quarters of year-over-year revenue growth and adjusted EBITDA growth, excluding Bausch + Lomb.
• More detail is expected with third-quarter results on Oct. 28.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bausch Health Companies Inc. published the original content used to generate this news brief on October 12, 2026, and is solely responsible for the information contained therein.